IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.

Wei ChenRichard N BamfordElijah F EdmondsonThomas A Waldmann

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

These studies support the initiation of a clinical trial in patients with cancer using IL15 in association with the checkpoint inhibitor, anti-PD-1, and intratumoral optimized anti-CD40.

Keyphrases

clinical trial
mouse model
dna damage
nk cells
cell cycle
open label
randomized controlled trial
phase ii
double blind